Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CONSORT MEDICAL PLC. We currently have 26 research reports from 5 professional analysts.
|02Dec16 09:25||RNS||Holding(s) in Company|
|01Dec16 09:43||RNS||Total Voting Rights|
|08Nov16 01:24||RNS||Director/PDMR Shareholding|
|01Nov16 10:15||RNS||Total Voting Rights|
|31Oct16 03:32||RNS||Director/PDMR Shareholding|
|31Oct16 01:00||RNS||Notice of Results|
|27Oct16 07:00||RNS||CIMZIA® AutoClicks® prefilled pen launched in UK|
Frequency of research reports
Research reports on
CONSORT MEDICAL PLC
CONSORT MEDICAL PLC
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
New impetus for injectables franchise
17 Oct 16
Bespak’s first deal for its proprietary Syrina autoinjector platform is with an undisclosed major global biopharma. Syrina is based on proprietary VapourSoft technology that uses a liquid gas propellant (rather than a conventional spring) to provide the force for drug delivery. Bespak’s ability to customise its devices to the specifications of its biopharma customers provides a significant competitive edge, enabling delivery of higher volumes and a broader range of formulations (including viscous biologics) while reducing the risk of safety hazards for users. This first deal provides technology validation and may catalyse further injectables deals. Bespak has the potential to become the partner of choice in an environment where rising numbers of biologic drugs in development and increased pressure on healthcare costs make self-administration a more attractive option.
Panmure Morning Note 14-10-2016
14 Oct 16
Consort Medical has announced that its Bespak division has entered into a master development agreement with an undisclosed global biopharmaceutical company, focused on Bespak's novel VapourSoft™ (gas propellant) driven autoinjector technology, Syrina™. Our assumption at this point is that the agreement is with a top-tier pharma and has the potential to be broad ranging in nature, representing very good validation of the VapourSoft platform. We make no change to forecasts at this point but consider both this and further potential deals represent excellent upside potential. Repeat Buy.
Approval should prompt wider interest in Bespak autoinjectors
19 Sep 16
UCB has received approval for the CIMZIA AutoClicks Prefilled Pen which uses Bespak autoinjector technology. This is the first biologic to be approved using the Bespak technology and we believe this experience will translate to increased interest in the remainder of the autoinjector portfolio; in our view a substantially undervalued part of Consort. In the interim, the consistent performance of the company due to long term contracts, in addition to the potential for growth from multiple new product launches over the next 6 months, makes Consort an attractive stock in uncertain markets. We retain our BUY recommendation and 1145p price target.
AZ reinforces Bespak strength in MDIs
09 Sep 16
Consort Medical and Astra Zeneca’s ‘significant’ new respiratory device supply agreement highlights the ongoing strength of Bespak’s metered dose inhaler (MDI) franchise. MDIs accounted for c 51% of the Bespak division’s total product revenues of £117.2m in FY16. This new multi-year agreement includes scale-up and supply of proprietary pMDI valves and actuators, which are critical components of AstraZeneca’s approved COPD (chronic obstructive pulmonary disease) therapy, Bevespi Aerosphere.
N+1 Singer - Morning Song 07-09-2016
07 Sep 16
Today’s update from Vectura is solid, highlighting respiratory royalty revenue ahead of previous expectations. The merger integration is well underway and expected to generate the targeted £10m of synergies by 2018e. We continue to forecast strong growth, propelled by mainly USD &EUR denominated royalty income from multiple products and flutiform® supply revenue. Key expected newsflow includes the US launch of LABA/LAMA drug Utibron® in H2 2016e and an FDA approval decision for VR315 (2nd to market generic Advair® partnered with Hikma) in May 2017. We continue to view Vectura as a core holding in the life sciences sector: Buy.
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 05-12-2016
05 Dec 16
RTHM is acquiring a profitable Canadian listed mobile specialist for equivalent of US$42.5m consideration in shares (88.235m). This helps adds to two growth vectors RTHM is targeting; (i) adds unique exclusive audience (10m unique) and (ii) Exclusive demand Yahoo and Facebook. The business has 15 premium and owned and operated apps which provide users with rewards for activity. The business is expected to deliver c$9m of EBITDA in FY18 including $2m of cost synergies. This equates to just 4.7x EV/EBITDA. This marks what we see the first step in RTHM activity to scale the business and deliver on margin potential (see our initiation notes). Our initial estimates for EPS revisions are very significant - for FY18 are 2.3 cents (currently 0.6) and for FY19 4.3 (currently 2.5). There is a call at 830 for investors and we will revise post this.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Panmure Morning Note 02-12-16
02 Dec 16
We expect CareTech to report FY results to September on 8th December. A positive trading update in October indicated that performance for the year was in line with market expectations therefore we are focusing on the outlook. We expect a confident statement since the end of 2016 showed positive trends across fee rates, expansion in places and occupancy. We believe CareTech is well positioned for further expansion, and remains at an attractive valuation. We retain our BUY and 380p price target.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.